Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.19
ALRPRB's Cash-to-Debt is ranked lower than
87% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. ALRPRB: 0.19 )
Ranked among companies with meaningful Cash-to-Debt only.
ALRPRB' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.14 Max: N/A
Current: 0.19
Equity-to-Asset 0.35
ALRPRB's Equity-to-Asset is ranked lower than
77% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. ALRPRB: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
ALRPRB' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.49  Med: 0.35 Max: 0.77
Current: 0.35
-0.49
0.77
Interest Coverage 0.24
ALRPRB's Interest Coverage is ranked lower than
99% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. ALRPRB: 0.24 )
Ranked among companies with meaningful Interest Coverage only.
ALRPRB' s Interest Coverage Range Over the Past 10 Years
Min: 0.24  Med: 0.64 Max: 1.37
Current: 0.24
0.24
1.37
Piotroski F-Score: 3
Altman Z-Score: 0.87
Beneish M-Score: -2.69
WACC vs ROIC
2.06%
1.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 1.88
ALRPRB's Operating Margin % is ranked lower than
51% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. ALRPRB: 1.88 )
Ranked among companies with meaningful Operating Margin % only.
ALRPRB' s Operating Margin % Range Over the Past 10 Years
Min: -44.13  Med: 3.85 Max: 7.6
Current: 1.88
-44.13
7.6
Net Margin % -1.64
ALRPRB's Net Margin % is ranked lower than
52% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. ALRPRB: -1.64 )
Ranked among companies with meaningful Net Margin % only.
ALRPRB' s Net Margin % Range Over the Past 10 Years
Min: -47.2  Med: -2.92 Max: 8.38
Current: -1.64
-47.2
8.38
ROE % -2.95
ALRPRB's ROE % is ranked lower than
52% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. ALRPRB: -2.95 )
Ranked among companies with meaningful ROE % only.
ALRPRB' s ROE % Range Over the Past 10 Years
Min: -34.13  Med: -3.78 Max: 9.33
Current: -2.95
-34.13
9.33
ROA % -0.65
ALRPRB's ROA % is ranked higher than
53% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. ALRPRB: -0.65 )
Ranked among companies with meaningful ROA % only.
ALRPRB' s ROA % Range Over the Past 10 Years
Min: -15.33  Med: -1.1 Max: 3.27
Current: -0.65
-15.33
3.27
ROC (Joel Greenblatt) % 0.94
ALRPRB's ROC (Joel Greenblatt) % is ranked higher than
51% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. ALRPRB: 0.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ALRPRB' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -169.25  Med: 10.95 Max: 22.61
Current: 0.94
-169.25
22.61
3-Year Revenue Growth Rate -1.00
ALRPRB's 3-Year Revenue Growth Rate is ranked lower than
66% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. ALRPRB: -1.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ALRPRB' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.6  Med: 10.1 Max: 73
Current: -1
-8.6
73
3-Year EBITDA Growth Rate -8.90
ALRPRB's 3-Year EBITDA Growth Rate is ranked lower than
68% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. ALRPRB: -8.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ALRPRB' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -39.2  Med: 6.9 Max: 102.9
Current: -8.9
-39.2
102.9
3-Year EPS without NRI Growth Rate -21.60
ALRPRB's 3-Year EPS without NRI Growth Rate is ranked lower than
70% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. ALRPRB: -21.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ALRPRB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -57.6  Med: -12.6 Max: 76.1
Current: -21.6
-57.6
76.1
GuruFocus has detected 5 Warning Signs with Alere Inc $ALRPRB.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ALRPRB's 30-Y Financials

Financials (Next Earnings Date: 2017-09-06 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ALRPRB Guru Trades in Q2 2016

Pioneer Investments 38,484 sh (unchged)
Howard Marks Sold Out
Private Capital 4,743 sh (-2.37%)
» More
Q3 2016

ALRPRB Guru Trades in Q3 2016

Private Capital 4,743 sh (unchged)
Pioneer Investments 38,484 sh (unchged)
» More
Q4 2016

ALRPRB Guru Trades in Q4 2016

Pioneer Investments 38,484 sh (unchged)
Private Capital 4,438 sh (-6.43%)
» More
Q1 2017

ALRPRB Guru Trades in Q1 2017

Pioneer Investments 38,484 sh (unchged)
Private Capital 4,338 sh (-2.25%)
» More
» Details

Insider Trades

Latest Guru Trades with ALRPRB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB376.473.193 % Conv Perp Pfd Shs Series -B-

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:OTCPK:JFIL, OTCPK:GBSN, OTCPK:MCUIF, OTCPK:OXIS, OTCPK:ETAH, OTCPK:IMEXF, NAS:ATOS, NAS:ROSG, OTCPK:VRTT, OTCPK:BMKDF, OTCPK:BTHCF, OTCPK:MTST, OTCPK:LEDIF, OTCPK:DIGP, OTCPK:BZYR, OTCPK:TBIO, OTCPK:EXDI, OTCPK:MDIT, NAS:TEAR, OTCPK:CRRVF » details
Traded in other countries:IM5.Germany,
Headquarter Location:USA
Alere Inc enables individuals to take charge of improving their health and quality of life at home. The Company operates in three segments; professional diagnostics, health information solutions and consumer diagnostics.

Alere develops rapid point-of-care diagnostic devices in cardiology, infectious disease, toxicology, diabetes, oncology, and women's health. North America accounts for the largest portion of the firm's revenue (55%), followed by Europe (19%), Asia-Pacific (14%), and the rest of the world (12%). Alere's headquarters are in Waltham, Massachusetts.

Ratios

vs
industry
vs
history
Forward PE Ratio 20.83
ALRPRB's Forward PE Ratio is ranked higher than
78% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. ALRPRB: 20.83 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
Price-to-Owner-Earnings 70.76
ALRPRB's Price-to-Owner-Earnings is ranked lower than
84% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. ALRPRB: 70.76 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALRPRB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.14  Med: 22.84 Max: 2417.22
Current: 70.76
9.14
2417.22
PB Ratio 2.87
ALRPRB's PB Ratio is ranked higher than
70% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. ALRPRB: 2.87 )
Ranked among companies with meaningful PB Ratio only.
ALRPRB' s PB Ratio Range Over the Past 10 Years
Min: 0.42  Med: 1.75 Max: 3.21
Current: 2.87
0.42
3.21
PS Ratio 1.72
ALRPRB's PS Ratio is ranked higher than
82% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. ALRPRB: 1.72 )
Ranked among companies with meaningful PS Ratio only.
ALRPRB' s PS Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.42 Max: 4.22
Current: 1.72
0.52
4.22
Price-to-Free-Cash-Flow 28.60
ALRPRB's Price-to-Free-Cash-Flow is ranked lower than
54% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. ALRPRB: 28.60 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALRPRB' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.03  Med: 19.99 Max: 168.64
Current: 28.6
7.03
168.64
Price-to-Operating-Cash-Flow 19.01
ALRPRB's Price-to-Operating-Cash-Flow is ranked higher than
57% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. ALRPRB: 19.01 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALRPRB' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.63  Med: 11.93 Max: 130
Current: 19.01
4.63
130
EV-to-EBIT 806.55
ALRPRB's EV-to-EBIT is ranked lower than
98% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. ALRPRB: 806.55 )
Ranked among companies with meaningful EV-to-EBIT only.
ALRPRB' s EV-to-EBIT Range Over the Past 10 Years
Min: -676  Med: 48.9 Max: 828.1
Current: 806.55
-676
828.1
EV-to-EBITDA 23.89
ALRPRB's EV-to-EBITDA is ranked lower than
67% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. ALRPRB: 23.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALRPRB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -173.6  Med: 13.9 Max: 87.3
Current: 23.89
-173.6
87.3
Current Ratio 2.14
ALRPRB's Current Ratio is ranked lower than
57% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. ALRPRB: 2.14 )
Ranked among companies with meaningful Current Ratio only.
ALRPRB' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.76 Max: 3.42
Current: 2.14
0.7
3.42
Quick Ratio 1.65
ALRPRB's Quick Ratio is ranked lower than
64% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. ALRPRB: 1.65 )
Ranked among companies with meaningful Quick Ratio only.
ALRPRB' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.35 Max: 2.89
Current: 1.65
0.46
2.89
Days Inventory 95.83
ALRPRB's Days Inventory is ranked lower than
57% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. ALRPRB: 95.83 )
Ranked among companies with meaningful Days Inventory only.
ALRPRB' s Days Inventory Range Over the Past 10 Years
Min: 80.21  Med: 92.61 Max: 104.46
Current: 95.83
80.21
104.46
Days Sales Outstanding 65.11
ALRPRB's Days Sales Outstanding is ranked lower than
54% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. ALRPRB: 65.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALRPRB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.28  Med: 67.28 Max: 79.93
Current: 65.11
60.28
79.93
Days Payable 58.14
ALRPRB's Days Payable is ranked higher than
53% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. ALRPRB: 58.14 )
Ranked among companies with meaningful Days Payable only.
ALRPRB' s Days Payable Range Over the Past 10 Years
Min: 45.36  Med: 52.02 Max: 59
Current: 58.14
45.36
59

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.19
ALRPRB's Dividend Yield % is ranked lower than
99.99% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.97 vs. ALRPRB: 3.19 )
Ranked among companies with meaningful Dividend Yield % only.
ALRPRB' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 4.66
Current: 3.19
0
4.66
Forward Dividend Yield % 3.19
ALRPRB's Forward Dividend Yield % is ranked lower than
99.99% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.15 vs. ALRPRB: 3.19 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.19
ALRPRB's 5-Year Yield-on-Cost % is ranked lower than
87% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. ALRPRB: 3.19 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ALRPRB' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 3.19
3-Year Average Share Buyback Ratio -2.20
ALRPRB's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. ALRPRB: -2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALRPRB' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -60.8  Med: -13 Max: 19.3
Current: -2.2
-60.8
19.3

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % 0.12
ALRPRB's Earnings Yield (Greenblatt) % is ranked lower than
59% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. ALRPRB: 0.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALRPRB' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 1.7 Max: 3.1
Current: 0.12
0.1
3.1

More Statistics

Beta-0.01
Short Percentage of Float0.00%
52-Week Range $271.04 - 389.79

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat